Vertex Pharmaceuticals logo

Vertex PharmaceuticalsVRTX

NASDAQ

Pharmaceuticals

$518.00-1.28%

AI Multi-Horizon Analysis

Short-term45% confidence
Neutral

Near-term price action likely to be driven by immediate news flow on pipeline or debt usage; absent catalysts, range-bound around $551.

Mid-term50% confidence
Neutral

Mixed financial signals with robust FCF and equity growth countered by margin pressure and higher leverage; insider buying provides mild support.

Long-term60% confidence
Bullish

Core CF franchise, record cash/FCF generation, and equity expansion support premium valuation if capital deployment yields pipeline success; margin and leverage trends require monitoring.

Overall AI View55% confidence
Neutral

Strong cash generation, revenue growth, and insider buying are offset by sharp margin compression, rising leverage from new debt, and liquidity contraction. Technical posture is mildly bullish on recent momentum but fundamentals are mixed.

Detailed AI Fundamental Analysis

Business Snapshot

Vertex Pharmaceuticals (VRTX) is a NASDAQ-listed commercial-stage biopharmaceutical company focused on pharmaceutical preparations, primarily developing and commercializing therapies for cystic fibrosis (CF) and other serious diseases. With approximately 6,400 employees and a market capitalization of $138.67 billion, the company has demonstrated consistent profitability and cash generation from its CF franchise. It maintains a strong balance sheet with significant cash reserves, though recent quarters show rising investment activity and the addition of long-term debt.

Financial Trends

Revenue has shown sequential growth in the last three reported quarters: Q3 2026 revenue rose 3.2% versus Q2 2026 ($3.441B vs $3.334B) and stands 15.2% higher than Q1 2026 ($3.441B vs $2.987B). Full-year 2025 revenue was $12.001B, indicating the quarterly run-rate has accelerated modestly into 2026.

Operating and net margins have compressed sharply in the latest period. Operating margin fell to 20.72% in Q3 2026 from 37.40% in Q2 2026 and 38.10% in Q1 2026 (a decline of 16.7 percentage points Q3 vs Q2). Net margin contracted to 19.00% in Q3 2026 from 32.99% in Q2 2026 and 34.53% in Q1 2026 (13.99 percentage point decline Q3 vs Q2). Compared with the year-ago December 2025 period (net margin 32.94%), the latest quarter reflects a 13.94 percentage point deterioration.

Free cash flow (FCF) trajectory has been strongly positive but variable. Q3 2026 FCF rose 23.6% sequentially to $2.854B from $2.308B in Q2 2026 and more than doubled versus Q1 2026 ($2.854B vs $1.295B). Full-year 2025 FCF was $3.194B, so the latest quarter alone nearly matches the entire prior-year annual total, signaling robust cash conversion despite margin pressure.

Balance-sheet strength has improved in equity but shows rising leverage and working-capital contraction. Shareholders’ equity grew steadily to $20.907B at 9/30/26 from $20.248B at 6/30/26, $19.362B at 3/31/26, and $18.666B at 12/31/25 (12.0% increase latest vs four periods ago). Total assets expanded 27.7% over the same span to $32.736B. However, total liabilities jumped 64.9% in Q3 2026 versus Q2 2026 ($11.829B vs $7.175B), driven by the addition of $3.497B in long-term debt (previously zero) and higher current liabilities. Current ratio declined to 2.34 from 3.19 in Q2 2026, and working capital fell to $6.686B from $8.606B, reflecting accelerated investment and financing activity.

Financial Health

The latest quarter (Q3 2026) shows a healthy but evolving financial position. Record-level cash from operations ($3.197B) and FCF ($2.854B) underscore the cash-generative power of the core business. Retained earnings continue climbing to $16.345B, and total equity reached an all-time high. However, the sharp margin compression, 64.9% sequential liability increase from new long-term debt, and contraction in liquidity metrics (current ratio down 0.85 points, working capital down $1.92B) indicate Vertex is in a phase of heavier capital deployment and balance-sheet recalibration. While still conservatively capitalized (debt/equity only 0.17), the trend toward higher leverage and lower operating efficiency bears watching; the company retains substantial cash ($4.979B) and a current ratio above 2.0, supporting ongoing R&D and potential business development.

Insider Activity

Insider sentiment over the 3-month window ending 11/09/26 is Neutral with a modest positive net tilt. Five buy transactions totaling $462,759 occurred with no offsetting sells in the reported data (net buy $462,759 across 6 filings). Notable recent purchases include a $400,259 buy by officer Brennan Daniel J. on 10/20/26 at $503.47 and smaller open-market buys by directors Sachs Bruce I and Garber Alan M in mid-October at $512.44. The absence of sells and cluster of director/officer purchases at prices 8-9% below the current $551.19 level signals quiet confidence from insiders.

Multi-Timeframe Technical Context

With the active timeframe labeled “fundamental” and session high/low data unavailable, price action context is limited to the current level of $551.19. The stock has appreciated meaningfully from the insider purchase cluster around $503–$512 in October 2026, implying positive short-term momentum. Absent explicit 1m–1D candle and indicator data, the technical picture defaults to a bullish bias on the back of the higher insider entry points and sustained uptrend from the 2025–2026 equity growth. Ultra-short (minutes) and short-term (hours–days) horizons will be driven by any immediate news flow around pipeline updates or debt issuance details, while the long-term (weeks–months) technical posture remains supported by record cash generation and expanding equity base.

Bull / Bear Cases

Short-term Bull Case (hours–days): Continued insider buying momentum, any positive read-through from the $3.2B operating cash flow print, or pipeline milestones could catalyze a move above recent highs. Margin pressure may be dismissed as one-time investment if management frames the debt raise as strategic.

Short-term Bear Case (hours–days): Sudden focus on the 16.7-point operating-margin contraction or the $3.5B debt addition could trigger profit-taking, especially if broader biotech sentiment weakens.

Long-term Bull Case (weeks–months): Sustained revenue growth, FCF exceeding $2.8B per quarter, and successful deployment of the new capital into high-ROI R&D or acquisitions could expand multiples. The CF franchise’s durability plus any new product launches would reinforce Vertex as a premium growth name with a fortress balance sheet.

Long-term Bear Case (weeks–months): If margin compression persists or debt-funded investments fail to yield visible pipeline progress, investors may question capital allocation. Competitive threats in CF or regulatory delays could stall the multi-year equity uptrend.

Key Levels & Triggers

  • Support: $503–$512 zone (recent insider buy cluster); $480–$490 (psychological 10–12% retracement from current levels).
  • Resistance: Immediate breakout above $560; psychological $600 level on strong pipeline news.
  • Triggers to Watch: Q4 2026 earnings (margin recovery or further compression), details on long-term debt use, clinical data readouts, and any shift in insider transaction pace. A sustained current ratio below 2.0 or further sharp margin erosion would be negative technical/fundamental confirmation. Positive FCF trends above $2.5B quarterly and equity growth continuing would reinforce the bullish fundamental thesis.

Financials

From SEC EDGAR · Period 2026-09-30 · Source form 10-Q

Income Statement · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-K
Revenue$3.44B$3.33B$2.99B$12.00B
Operating Income$712.90M$1.25B$1.14B$4.17B
Net Income$653.60M$1.10B$1.03B$3.95B
EPS (Diluted)$2.56$4.31$4.02$15.32
Operating Margin20.72%37.40%38.10%34.77%
Net Margin19.00%32.99%34.53%32.94%

Balance Sheet · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-Q
Total Assets$32.74B$27.42B$26.48B$25.64B
Total Liabilities$11.83B$7.18B$7.12B$6.98B
Shareholders' Equity$20.91B$20.25B$19.36B$18.67B
Cash & Equivalents$4.98B$6.14B$5.49B$5.08B
Long-term Debt$3.50B——$0.00
Current Ratio2.343.193.022.90
Debt / Equity0.17———

Cash Flow · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-K
Cash from Operations$3.20B$2.55B$1.43B$3.63B
Cash from Investing-$6.58B-$477.70M-$431.90M-$945.40M
Cash from Financing$3.33B-$965.50M-$538.80M-$2.26B
Capital Expenditures$342.90M$245.60M$133.40M$437.60M
Free Cash Flow$2.85B$2.31B$1.29B$3.19B

Income Statement

Revenue
$9.76B
Gross Profit
—
Operating Income
$3.10B
Net Income
$2.78B
EPS (Basic)
$10.98
EPS (Diluted)
$10.90

Balance Sheet

Total Assets
$32.74B
Total Liabilities
$11.83B
Shareholders' Equity
$20.91B
Cash & Equivalents
$4.98B
Long-term Debt
$3.50B
Shares Outstanding
253.54M

Cash Flow

Cash from Operations
$3.20B
Cash from Investing
-$6.58B
Cash from Financing
$3.33B
Capital Expenditures
$342.90M
Free Cash Flow
$2.85B

Key Ratios

Gross Margin
—
Operating Margin
31.74%
Net Margin
28.53%
Current Ratio
2.34
Debt / Equity
0.17
Free Cash Flow
$2.85B

Insider Activity

3 insider filings (2026-10-10 to 2026-11-09) — sourced directly from SEC Forms 4/5

Buys
$462.8K · 3
Sells
$0.00 · 0
Net
$462.8K
Filings Parsed
3
Trade DateInsiderActionSharesPriceValue
2026-10-20Brennan Daniel J.Buy795$503.47$400.3K
2026-10-15SACHS BRUCE IBuy92.694$512.44$47.5K
2026-10-15Garber Alan MBuy29.272$512.44$15.0K

Key Stats

$130.54BMarket cap
$510.7752-week high
$362.5052-week low
1,228,977Avg volume (30d)

6,400 employees253.46M shares outstandinglisted 1991-07-31

Next earnings ~May 5, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Latest News

VRTX catalysts

We track VRTX on Sector Watch from primary sources. See its FDA dates, trials and filings

Related Stocksin Pharmaceuticals

Related research

More in Market history

Ready to see the live AI view on VRTX?

Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing VRTX side-by-side with live signals.